https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/ONC/beone-medicines-esmo-2026-solid-tumor-franchise BiopharmaWatch en 2026-10-19T10:00:00.000Z BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 https://www.biopharmawatch.com/news/IDYA/darovasertib-potential-foundational-therapy-uveal-melanoma BiopharmaWatch en 2026-10-19T10:00:00.000Z IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma https://www.biopharmawatch.com/news/ZYME/zymeworks-appoints-suzanne-monahan-svp-commercial BiopharmaWatch en 2026-10-19T10:00:00.000Z Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma https://www.biopharmawatch.com/news/BDSX/biodesix-digital-diagnostics-lung-pipeline BiopharmaWatch en 2026-10-19T10:00:00.000Z Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers https://www.biopharmawatch.com/news/BLTE/belite-bio-uplisting-nasdaq-global-select-market BiopharmaWatch en 2026-10-19T10:00:00.000Z Belite Bio Announces Uplisting to the Nasdaq Global Select Market https://www.biopharmawatch.com/news/TAK/entivyo-ulcerative-colitis-trial-results BiopharmaWatch en 2026-10-19T09:30:00.000Z First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication https://www.biopharmawatch.com/news/NUTX/nutex-health-2026-q3-financial-results-call BiopharmaWatch en 2026-10-19T09:30:00.000Z Nutex Health Schedules 2026 Third Quarter Financial Results Release and Conference Call https://www.biopharmawatch.com/news/LLY/lilly-omvoh-phase-3-results-pediatric-ulcerative-colitis BiopharmaWatch en 2026-10-19T08:40:00.000Z Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis https://www.biopharmawatch.com/news/ABBV/abbvie-abbv-466-crohns-disease-results BiopharmaWatch en 2026-10-19T08:00:00.000Z AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-19 BiopharmaWatch en 2026-10-19T07:15:25.407Z BIOA APJ program: Biotech Catalysts Oct 19, 2026 https://www.biopharmawatch.com/news/WAT/ultima-genomics-immune-profiling-study-uk-biobank BiopharmaWatch en 2026-10-19T07:05:00.000Z Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation https://www.biopharmawatch.com/news/EVAX/evaxion-three-year-follow-up-phase-2-trial-evx-01 BiopharmaWatch en 2026-10-19T07:00:00.000Z Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 https://www.biopharmawatch.com/news/OCS/oculis-predict-1-trial-licaminlimab-dry-eye BiopharmaWatch en 2026-10-19T06:00:00.000Z Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease https://www.biopharmawatch.com/news/TLX/telix-ekalia-collaborate-astatine-211-production-us BiopharmaWatch en 2026-10-19T05:30:00.000Z Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S. https://www.biopharmawatch.com/news/NTRA/natera-esmo-2026-abstracts-ultrasensitive-mrd-technology BiopharmaWatch en 2026-10-18T22:10:00.000Z ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology https://www.biopharmawatch.com/news/ABBV/abbvie-esmo-2026-oncology-data-presentation BiopharmaWatch en 2026-10-18T22:10:00.000Z AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio https://www.biopharmawatch.com/news/LLY/lilly-showcase-oncology-pipeline-esmo-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress https://www.biopharmawatch.com/news/INCY/incyte-oncology-data-esmo-congress-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/ZNTL/zentalis-azenosertib-overall-survival-data-esmo-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-abstracts-esmo-congress-2026 BiopharmaWatch en 2026-10-18T22:05:00.000Z Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress https://www.biopharmawatch.com/news/MANE/veradermics-conference-call-phase-3-results-hair-loss BiopharmaWatch en 2026-10-18T22:00:00.000Z Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss https://www.biopharmawatch.com/news/IRON/disc-medicine-webcast-apollo-phase-3-results BiopharmaWatch en 2026-10-18T21:00:00.000Z Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-uegw-2026-presentations BiopharmaWatch en 2026-10-18T13:30:00.000Z Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026